Pharmaceutical and biotechnology organizations have made significant progress enabling accelerated drug discovery with traditional laboratory and computing methods. However, they have only just begun to harness the potential of artificial intelligence (AI) to develop more effective therapeutics faster.
This article looks at recent work from researchers at GlaxoSmithKline (GSK) with Cerebras Systems as an example of how the right AI computing platform can enable new research and new methods and potentially transform the future of drug discovery.
Inside the GSK and Cerebras partnershipGSK and Cerebras Systems have a partnership that uses AI computing from Cerebras to accelerate pharmacological and life sciences research at GSK. As a recent example of the power of this partnership, GSK researchers worked with Cerebras Systems to develop a new AI model of cell-type-specific gene re…